Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Neurology ; 88(4): 352-358, 2017 01 24.
Article in English | MEDLINE | ID: mdl-27986876

ABSTRACT

OBJECTIVE: To examine the development of factors associated with insomnia in a cohort of originally drug-naive patients with incident Parkinson disease (PD) during the first 5 years after diagnosis. METHODS: One hundred eighty-two drug-naive patients with PD derived from a population-based incident cohort and 202 control participants were assessed for insomnia before treatment initiation and were repeatedly examined after 1, 3, and 5 years. Insomnia was diagnosed according to the Stavanger Sleepiness Questionnaire. The Parkinson's Disease Sleep Scale was used to differentiate sleep initiation problems from problems of sleep maintenance. Generalized estimating equation models were applied for statistical measures. RESULTS: The prevalence of insomnia in general was not higher in patients with PD compared to controls at the 5-year follow-up. There were changes in the prevalence of the different insomnia subtypes over the 5-year follow-up. The prevalence of solitary problems in sleep maintenance increased from 31% (n = 18) in the drug-naive patients at baseline to 49% (n = 29) after 1 year and were associated with the use of dopamine agonists and higher Montgomery-Åsberg Depression Rating Scale scores. The prevalence of solitary sleep initiation problems decreased continuously from 21% (n = 12) at baseline to 7.4% (n = 4) after 5 years; these were associated with less daytime sleepiness. CONCLUSIONS: The prevalence rates of the different insomnia subtypes changed notably in patients with early PD. The frequency of sleep maintenance problems increased, and these problems were associated with dopamine agonist use and depressive symptoms, while the total number of patients with insomnia remained stable. Our findings reflect the need for early individual assessments of insomnia subtypes and raise the possibility of intervention to reduce these symptoms in patients with early PD.


Subject(s)
Parkinson Disease/complications , Sleep Initiation and Maintenance Disorders/classification , Sleep Initiation and Maintenance Disorders/complications , Aged , Antiparkinson Agents/adverse effects , Antiparkinson Agents/therapeutic use , Depression/complications , Depression/epidemiology , Dopamine Agonists/adverse effects , Dopamine Agonists/therapeutic use , Female , Follow-Up Studies , Humans , Incidence , Longitudinal Studies , Male , Parkinson Disease/drug therapy , Parkinson Disease/epidemiology , Parkinson Disease/psychology , Prevalence , Prospective Studies , Psychiatric Status Rating Scales , Sleep Initiation and Maintenance Disorders/epidemiology , Sleep Initiation and Maintenance Disorders/psychology , Surveys and Questionnaires , Time Factors
2.
Neurology ; 85(2): 162-8, 2015 Jul 14.
Article in English | MEDLINE | ID: mdl-26085603

ABSTRACT

OBJECTIVE: To examine the frequency, development, and risk factors of excessive daytime sleepiness (EDS) in a cohort of originally drug-naive patients with incident Parkinson disease (PD) during the first 5 years after diagnosis. METHODS: One hundred fifty-three drug-naive patients with early PD derived from a population-based incident cohort and 169 control participants were assessed for EDS and reevaluated after 1, 3, and 5 years on medication. EDS was diagnosed according to the Epworth Sleepiness Scale. Cutoff score above 10 was applied. Generalized estimating equation models for correlated data were used to examine associated and risk factors for EDS. RESULTS: Patients reported EDS more often than control participants at the time of diagnosis and during follow-up. The frequency of EDS in PD increased from 11.8% at baseline to 23.4% after 5 years. Associated factors were male sex, the use of dopamine agonists, and higher Montgomery-Åsberg Depression Rating Scale and Unified Parkinson's Disease Rating Scale-activities of daily living scores. Main risk factor for developing EDS was an increased Epworth Sleepiness Scale score at baseline. CONCLUSION: EDS is more frequent in PD even before treatment initiation compared with control participants and increases in occurrence with disease progression. The main risk factor for developing EDS with time is an early predisposition for sleepiness. In addition, the use of dopamine agonists was associated with the development of EDS. These findings necessitate caution in patients with PD and early increased sleep propensity and when using dopamine agonists.


Subject(s)
Antiparkinson Agents/adverse effects , Disorders of Excessive Somnolence/etiology , Parkinson Disease/complications , Parkinson Disease/drug therapy , Aged , Cohort Studies , Dopamine Agonists/adverse effects , Female , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...